Quinolones, a popular and powerful anti-biotic with broad coverage and reasonable safety, was concerned to be associated with acute liver failure (ALF). A study published in the Journal of Gastroenterology and Hepatology on 14 March 2021 by, among others, RSI’s Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski, investigated the risk of ALF within 30 days after receiving a systemically administered dose of the quinolone antibiotic, in individuals with no history of liver diseases.
Although the primary analysis did not reveal an overall association between quinolones as a class and ALF risk, a possible risk was identified among those with no or few comorbidities, those ≤ 60 years of age, women, men, African Americans, and Caucasians.
The authors noted that elevated risks seen in some subgroups warrant further investigation.
The paper is available by clicking here.